An innovative light-activated therapy developed at The Institute of Cancer Research, London, could help detect and treat an aggressive brain cancer type, a new study shows.
Jun 20, 2022
0
112
A recent research paper published in Nature Communications by a team led by Yale School of Medicine researchers finds a promising way to make brain cancer cells more susceptible to chemotherapy.
May 17, 2022
0
53
Findings from a seven-year research project suggests that there could be a new approach to treating one of the most common and devasting forms of brain cancer in adults—Glioblastoma Multiforme (GBM).
May 9, 2022
0
105
Based on the findings of a new study led by the Translational Genomics Research Institute (TGen), part of City of Hope, a coast-to-coast clinical trial is planned that, if successful, could lead to FDA approval of the first ...
May 3, 2022
0
70
Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme (GBM), the most common and most aggressive type of malignant brain tumor. ...
Feb 9, 2022
0
40
Short bursts of radiation therapy dramatically enhanced the efficiency of targeting glioblastomas with natural nanoparticle-based immunotherapy, thus suppressing growth of the deadly tumor, inducing anti-tumor immunity and ...
Jan 31, 2022
0
135
Glioblastoma, an aggressive cancer in the brain or spinal cord, has proven stubbornly resistant to newer immunotherapies. And radiation and chemotherapy, the standard treatment for glioblastoma, result in fewer than 10 percent ...
Jan 19, 2022
0
133
Researchers at the University of Sussex are one step further to developing a blood test capable of diagnosing the most aggressive form of brain tumor.
Jan 17, 2022
0
97
Glioblastoma is widely considered the most aggressive brain cancer. Even with treatment, patient survival rates are low, with most living an average of 15–18 months after diagnosis. Because of the highly diverse characteristics ...
Dec 21, 2021
0
77
Northwestern Medicine scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas—the most common and malignant of primary brain tumors—might benefit from immunotherapy.
Nov 29, 2021
0
73
